6[1]Eatock MM, Schatzlein A, Kaye SB. Tumor vasculature as a target for anticancer therapy [J]. Cancer Treat Rev, 2000; 26(3):191-204.
7[2]Ostrowski K, Kinsner A. Inhibition of angiogenesis in the treatment of tumors [J]. Arch Immunol Ther Exp (Warsz), 2001; 49(1):27-31.
8[3]Mikasa k, Sawaki M, Kita E, Hamada K, Konishi M, Meada K, Teramota S, Takeuchi S, Fukuoka K, Sakamoto M, Tsujimoto M, Mori K, Kunimatsu M, Kashiba S, Narita N. Clarithromycin in the long-term treatment of primary lung cancer: Possibility of clarithromycin as a biological response modifier [J]. Chemotherapy, 1994; 42(3):1293-1298.
9[4]Konno SM, Adachi k, Asano T, Okamoto TK. Influence of roxithromycin on the cell-mediated immune responses [J]. Life Sci, 1992; 51(1):107-112.
10[5]Mikasa K. Study of effects and mechanisms of macrolide as biological response modifier for lung cancer treatment [J]. Jpn J Antibiot, 2000; 53(4):253-260.
